News
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026 Monotherapy and multi-regimen combination data demonstrate a cytopenia-sparing safety profile, robust CD47 receptor occupancy, and encouraging dose-dependent antitumor activity HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical and translational data on HCB101, its […]
Feb 19, 2026
Read more
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to […]
Feb 13, 2026
Read more
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026 Sustained execution and high-impact data across HanchorBio’s next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today announced a robust schedule of scientific presentations at […]
Feb 05, 2026
Read more
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
Jan 26, 2026
Read more
HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101
HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101 Patent Approval Strengthens Global Intellectual Property Position and Supports International Licensing Strategy HanchorBio today announced that the Japan Patent Office (JPO) had granted Japanese Patent No. 7795041 covering engineered SIRPα variants and their therapeutic use, providing intellectual property protection for HCB101, the company’s differentiated […]
Jan 23, 2026
Read more
HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026
HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026 As the holiday season approaches, HanchorBio is kicking off 2026 with active engagement at one of the industry’s most important global healthcare events. HanchorBio is participating in the J.P. Morgan Healthcare Conference 2026, held January 12–15, 2026, in San Francisco. During the conference, Scott Liu, PhD, Founder, Chairman, and […]
Jan 14, 2026
Read more
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation Mid-dose cohorts demonstrate ~80% ORR when HCB101 is layered on the standard ramucirumab and paclitaxel in second-line gastric cancer. HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today […]
Jan 09, 2026
Read more
HanchorBio 2025 Milestones
HanchorBio 2025 Milestones Patient First, Data Driven. HanchorBio is a clinical-stage biotechnology company advancing differentiated immuno-oncology biologics through its proprietary FBDB™ (Fc-Based Designer Biologics) platform. In 2025, the platform achieved meaningful validation across clinical development, global scientific recognition, intellectual property, and capital markets, marking its transition from platform build-out to clinical execution. FBDB™ Platform Overview […]
Dec 29, 2025
Read more
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025 International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors [Taipei, Shanghai, and San Francisco | December 12, 2025] –HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and […]
Dec 12, 2025
Read more
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL) HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, presented new first-in-human data […]
Dec 09, 2025
Read more